| Product Name | Beta-Amyloid (1-42), HFIP-Treated |
| Catalog Number | LT9155 |
| Product Quantity | 0.5 mg |
| Sequence / Form | DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA; HFIP-treated |
| Molecular Weight | 4514.4 |
| Purity | ≥95% |
| Mechanism & Biological Significance | Aβ42 is highly aggregation-prone. HFIP monomerization/film preparation is commonly used to minimize pre-existing assemblies and improve experimental reproducibility before controlled oligomer or fibril generation. |
| Published Research Context | Peer-reviewed studies directly prepared Aβ1-42 with HFIP according to established Stine-type methods, and published cell/exosome work explicitly used HFIP-treated human Aβ1-42 in aggregation experiments. |
| Research Applications | - Aβ42 oligomer and fibril preparation
- aggregation kinetics
- cellular uptake and glial/exosome studies
- standardized amyloid assay workflows
|
| Experimental Considerations | HFIP pretreatment is part of this reagent's preparation history. It is not chemically interchangeable with an untreated Aβ42 lot because residual assembly state and subsequent oligomer/fibril kinetics depend strongly on pretreatment. |
| Selected Scientific References | - In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis
|
